Matthew Moye

Matthew Moye is an Associate Director at Merck & Co. within Quantitative Pharmacology and Pharmacometrics (QP2), focusing on developing quantitative systems pharmacology models for neurodegenerative diseases. Previously, Matthew served as a Postdoctoral Fellow in QP2 and was a PhD Candidate at the New Jersey Institute of Technology, where their dissertation research centered on estimating mathematical models using data assimilation. Matthew also gained experience as a Research Intern at IBM, concentrating on brain nuclei models for large-scale network simulations. They hold a Bachelor of Science in Quantitative Biology from the University of Delaware, where they conducted research on numerical solutions and compartmental models of the tear film.